Case-control Indian buffet process identifies biomarkers of response to Codrituzumab

Melanie F. Pradier1,9*, Bernhard Reis2, Lori Jukofsky3, Francesca Milletti4,7, Toshihiko Ohtomo5, Fernando Perez-Cruz6,9 and Oscar Puig3,8

Abstract

Background: Codrituzumab, a humanized monoclonal antibody against Glypican-3 (GPC3), which is expressed in hepatocellular carcinoma (HCC), was tested in a randomized phase II trial in advanced HCC patients who had failed prior systemic therapy. Biomarker analysis was performed to identify a responder population that benefits from treatment.

Methods: A novel statistical method based on the Indian buffet process (IBP) was used to identify biomarkers predictive of response to treatment with Codrituzumab. The IBP is a novel method that allows flexibility in analysis design, and which is sensitive to slight, but meaningful between-group differences in biomarkers in very complex datasets.

Results: The IBP model identified several subpopulations of patients having defined biomarker values. Tumor necrosis and viable cell content in the tumor were identified as prognostic markers of disease progression, as were the well-known HCC prognostic markers of disease progression, alpha-fetoprotein and Glypican-3 expression. Predictive markers of treatment response included natural killer (NK) cell surface markers and parameters influencing NK cell activity, all related to the mechanism of action of this drug.

Conclusions: The Indian buffet process can be effectively used to detect statistically significant signals with high sensitivity in complex and noisy biological data.

Trial registration: NCT01507168, January 6, 2012

Keywords: Codrituzumab, Indian buffet process, Natural killer cells

Background

The cell surface heparan sulfate proteoglycan Glypican-3 (GPC3) is a serological and histochemical marker of hepatocellular carcinoma (HCC), due to its high and specific expression in HCC [1]. GPC3 promotes the growth of HCC by stimulating Wnt signaling [2], and GPC3 suppression inhibits growth of HCC cells via upregulation of TGF-β2 [3].

The anti-human GPC3 humanized monoclonal antibody Codrituzumab binds to GPC3 with high affinity [4] and interacts with CD16/FcγRIIIa, a receptor in Natural Killer (NK) cells to trigger antibody-dependent cytotoxicity (ADCC) [5]. Phase I studies in the US [6] and Japan [7] showed that Codrituzumab was well tolerated up to 20 mg/kg/wk. without dose limiting toxicity. These results led to a Phase II study to determine efficacy, in which Codrituzumab was well tolerated but did not meet pre-specified efficacy endpoints [8]. However, secondary analyses of data from the study found longer overall survival in patients with higher levels of Glypican-3 or CD16, indicating that a patient stratification strategy might improve outcomes.

In order to identify patients who might best respond to Codrituzumab, we conducted a retrospective analysis of biomarker data from the Phase II study, including demographic information, tumor histology, as well as serum and blood biomarkers. Variable drug exposure, observed in the treatment arm, confounded standard statistical approaches such as regression models [8]. Therefore, a novel probabilistic approach for clinical data analysis, the case-control Indian Buffet Process...
performed on four patients in the tumor sample prior to study entry. IHC was used to determine the level of GPC3 expression in tumor tissue sample. Centrally reviewed immunohistochemistry (IHC) was performed on sections of formalin-fixed, paraffin-embedded blocks of the primary tumor (or the metastatic site) which had been obtained within approximately 12 months prior to informed consent. If no archival material was available, a pre-treatment core needle biopsy (using an 18-gauge or larger needle) was obtained and the sample fixed in formalin, embedded in paraffin and prepared as above. The IHC staining was done on BenchMark XT (Ventana Medical Systems, Inc. or VMSI, catalog number 750–700) or ULTRA (VMSI, catalog number 750–600) platforms. Each patient was assigned a GPC3 IHC score with ordered categorical values 0, 1+, 2+, and 3+, corresponding to increasing levels of GPC3 expression, with scores 0 and 3+ indicating the lowest and highest levels of GPC3 expression, respectively.

Flow cytometry
Surface cell markers from circulating blood cells were measured by flow cytometry. Lymphocyte subsets were assayed using Trucount tubes (Becton, Dickinson and Company or BD, catalog number 340334). The expression level of CD16 on NK cells was measured by flow cytometry analysis of the pre-treatment peripheral blood mononuclear cells using a CD16-specific monoclonal antibody. Measurement was done on FACS CantoTM II (BD, catalog number 657338). CD16 expression level, or fluorescence intensity in units of Molecules of Equivalent Soluble Fluorochrome (MESF), denoted by CD16 MESF, was calculated by converting fluorescence measurements of the NK cell population to an MESF value based on an MESF calibration curve generated using the fluorescence intensity of calibration beads (QuantumTM MESF bead standard, manufactured by Bang Laboratories, IN, USA) [10].

Soluble protein measurements
Monoclonal antibodies against soluble GPC3 protein were generated as previously described [11]. Five anti-N-terminal fragment mAbs (designated GT30, GT95, GT114, GT165 and GT607), and two anti-C-terminal fragment mAbs (designated GT57 and M3C11), were used in combination in four different assays (sGP3C 114/165, sGP3C 30/57, sGP3C 30/607, sGP3C 11/96) to detect full length GPC3 protein, or any possible cleavage fragments containing N- or C-terminus. The protocol for sandwich ELISA assay has been described [11].

DNA polymorphisms
Genomic DNA was extracted from blood samples with a QiAmp Blood Mini Kit (Qiagen, Germany). DNA concentrations were measured with NanoDrop ND-1000 (Thermo Fisher Scientific, Wilmington, DE, USA), and DNA samples were diluted in nuclease free water to get a final concentration of 1 ng/μl. TaqMan technology on Applied Biosystems (AB) 7500 Fast Real-Time PCR system (Applied Biosystems Inc., CA, USA) was used to genotype patients for two different Fc gamma receptor polymorphisms, FcgRIIa-H131R and FcgRIIa-V158F. We used probes and primers (TaqMan SNP Assays for
rs1801274 and rs3969991) from Applied Biosystems. Genotyping was performed following the manufacturer’s instructions.

Statistical analysis

The Case-Control Indian Buffet Process (C-IBP) is an unsupervised approach to discover patient subgroups and common correlation patterns among the biomarker values. In particular, C-IBP finds a meaningful representation of patients by decomposing the data matrix X into the product of two matrices that are learned from data: a dictionary matrix B and a binary feature-activation matrix Z. Matrix B corresponds to the correlation patterns (also called latent features) that are most present in the data. Matrix Z indicates which features are active or absent for each patient individually.

In order to deal with the small sample-size scenario typical from clinical trials, C-IBP shares information between patients in the placebo and treatment arm. More particularly, C-IBP allows for two types of latent features: global features and treatment-specific features. Global features are learned from patients in the placebo arm, and can be active for any patient, capturing general patterns in the patient population, regardless of any treatment. In contrast, drug-specific features are learned from treated patients, and can only be active for patients in the treatment arm, capturing correlations linked to the effect of the drug.

The C-IBP approach was first used to identify subpopulations of patients having similar correlation patterns of biomarker values. The model describes each subpopulation using a specific signature of latent features that can be either present or absent. Progression Free Survival (PFS) for each subpopulation was monitored and groups with better survival outcome were identified. PFS was the clinical endpoint of the clinical trial. A biomarker analysis for each subgroup was conducted to identify statistically significantly associated biomarkers. Assessment of statistical significance for each biomarker was performed using the Mann Whitney test for continuous variables and the Fisher test for discrete variables. In order to account for multiple hypothesis testing we followed the Benjamini and Hochberg procedure to estimate False Discovery Rate and adjust statistical significance levels [12]. An illustration of the whole pipeline and further details can be found in the Additional file 1.

Results

180 patients (120 in the treatment arm, 60 in the placebo arm) with HCC were enrolled in a randomized, placebo-controlled, double-blind, multicenter phase II trial of Codrituzumab. The primary efficacy endpoint was not met, and when a population pharmacokinetic (PK) analysis was performed, a highly varied range of drug exposure in the treatment arm was observed, resulting in only half of the patients receiving appropriate drug exposure [8]. In order to identify subgroups of patients benefiting from the drug, we performed a comprehensive retrospective biomarker analysis using standard techniques (list of biomarkers shown in Additional file 2 and biomarker data in Additional file 3), however, standard statistical approaches did not find any significant biomarkers, probably because of the variable and heterogeneous nature of the data [8]. Alternatively, the C-IBP is a novel probabilistic approach to clinical data analysis which was able to deliver statistically significant biomarkers.

Latent feature analysis

We used Progression Free Survival (PFS) as a clinical endpoint in our analysis. As shown in Table 1, the C-IBP model identified twelve subpopulations from the set of 180 patients, and three latent features (F1, F2, and F3) which capture correlation patterns of biomarker values. These features can be either present (=1) or absent (=0) for each patient individually. A feature is present when the corresponding pattern contributes to the total biomarker values of that patient. A subpopulation is defined as a group of patients having similar biomarker values, encoded by the same set of present features. The C-IBP model is constrained to identify two types of features: global features, which can be active for any patient (F1 and F2), and drug-specific features, which can only be active for patients in the treatment arm (F3). The number of each type of latent feature was not fixed beforehand but learned from data.

Tables 2, 3, 4 contain the biomarkers that are statistically significant in relation to each of the three features (F1-F3). The sign (+ or -) indicates the direction of the biomarker effect in the case group versus the control group, such that positive effect means that the biomarker has a higher value in the case group versus the control group. Feature F1 is represented by high levels of alpha-fetoprotein and GPC3 expression both in tumor (GPC3 cytoplasmic and membrane IHC staining) and as soluble protein sGPC3 (as detected by four serum assays), as shown in Tables 2, 3, 4 and Additional file 4). Feature F2 is associated with higher levels of inflammatory T and NK cells (positively stained for CD3/CD16) in tumor necrotic tissue and adjacent peritumoral stroma, and low levels of CD3/CD16 in viable tumor cells (Table 3 and Additional file 4). The combination of F1 and F2 is associated with better prognosis. Feature F3, the feature associated with drug treatment, is associated with higher levels of T (CD3, CD45) and NK (CD16, NKp46) cell markers (Table 4 and Additional file 4).
Analysis of subpopulations

One of the outstanding properties of the C-IBP method is its flexibility in analyzing complex datasets, allowing a detailed analysis of subpopulations by using shared features to group them. For example, in the placebo arm, the C-IBP model found (learned from the data) four subpopulations (groups 1 to 4 in Table 1). Subpopulation 4 has a much higher PFS compared with the other three subgroups, indicating better prognosis in the absence of treatment. Out of the 70 variables analyzed simultaneously by the C-IBP method, higher levels of inflammatory T and NK cells (CD3/CD16) in tumor necrotic tissue and adjacent peri-tumoral stroma, and lower levels in viable cells in tumor (CD3/CD16 staining in viable tumor cells) correlate with better prognosis (Table 5).

In the treatment arm (groups 5 to 12 in Table 1), subpopulations with feature F3 active (6, 8, 10 and 12) have higher PFS values compared with the similar subpopulation in which F3 is not active. The effect of F3 on prolonged survival was found across all subpopulations, as seen by pairwise comparisons between subpopulations in the treatment arm with F3 active vs. the ones with F3 inactive (eg. 5 vs 6, 7 vs 8, etc). Table 6 shows that biomarkers correlating with F3 in the treatment group are similar to the ones correlating with F3 globally (Table 4), i.e., higher levels in blood of inflammatory T (CD3, CD45) and NK (CD16, NKp46) cells.

High drug exposure analysis

Patients received intravenous Codrituzumab at a dose of 1600 mg every two weeks (Q2W), however, drug exposure measurements showed that drug levels varied considerably among patients. We therefore repeated the biomarker statistical analysis using biomarker data only from patients with high Codrituzumab exposure (above median) compared to placebo. Table 7 (to be compared with Table 1) shows the 12 subpopulations and 3 features found by the

### Table 1: Subpopulations discovered by the Case-Control Indian Buffet Process (C-IBP)

| Sub-population | Drug Identifier | F1 | F2 | F3 | Average(*) num. of patients | Mean PFS (month) | Median PFS (month) |
|----------------|----------------|----|----|----|----------------------------|-----------------|-------------------|
| 1              | 0              | 0  | 0  | 0  | 33.37                      | 3.06            | 1.65              |
| 2              | 0              | 0  | 1  | 0  | 4.07                       | 2.29            | 2.24              |
| 3              | 0              | 1  | 0  | 0  | 17.84                      | 2.72            | 1.81              |
| 4              | 0              | 1  | 1  | 0  | 4.72                       | 7.05            | 7.18              |
| 5              | 1              | 0  | 0  | 0  | 51.52                      | 3.22            | 2.55              |
| 6              | 1              | 0  | 0  | 1  | 16.77                      | 4.17            | 3.65              |
| 7              | 1              | 0  | 1  | 0  | 8.38                       | 1.74            | 1.33              |
| 8              | 1              | 0  | 1  | 1  | 2.07                       | 2.69            | 2.65              |
| 9              | 1              | 1  | 0  | 0  | 29.88                      | 3.36            | 2.03              |
| 10             | 1              | 1  | 0  | 1  | 4.90                       | 4.44            | 4.34              |
| 11             | 1              | 1  | 1  | 0  | 4.53                       | 6.31            | 5.31              |
| 12             | 1              | 1  | 1  | 1  | 1.94                       | 10.04           | 10.01             |
| Total          | 120.0          | 63.82 | 25.72 | 25.69 | 180 | 3.44 | 2.04 |

Three latent features (F1, F2, F3) describe the population in this study, and each subpopulation can have the feature active (1) or inactive (0). Mean PFS was used as meaningful clinical endpoint. (*) Average number of patients is reported since the C-IBP is a probabilistic method that allows for soft-clustering of the patients (each patient belong to a subpopulation with a certain probability).

### Table 2: Biomarkers significant for feature F1, ranked by effect size

| Continuous Variables | Effect Size | p-value |
|----------------------|-------------|---------|
| AFP                  | 3.65        | 1.31e-07|
| GPC3 membrane        | 1.30        | 1.53e-21|
| GPC3 cytoplasmic     | 0.69        | 2.08e-16|
| sGPC3 11/96          | 0.47        | 1.34e-04|
| sGPC3 30/57          | 0.40        | 1.53e-05|
| sGPC3 30/607         | 0.34        | 6.21e-10|
| sGPC3 114/165        | 0.32        | 2.48e-10|

AFP, alpha-fetoprotein; GPC3 membrane, GPC3 expression, as measured by H score in cell membrane; GPC3 cytoplasmic, same as before, but measure in cell cytoplasm; sGPC3, are the different soluble assays against serum GPC3.

### Table 3: Biomarkers significant for feature F2, ranked by effect size

| Continuous Variables | Effect Size | p-value |
|----------------------|-------------|---------|
| CD3/CD16 necrotic    | 3.94        | 1.29e-17|
| %Necrotic            | 3.91        | 9.39e-18|
| CD3/CD16 viable      | -1.27       | 1.29e-17|
| %Viable              | -1.24       | 9.39e-18|

CD3/CD16 necrotic/viable, staining for CD3 and CD16 in the necrotic tissue and viable cells respectively; %Necrotic/%Viable: percentage of necrotic or viable cells in tissue; AAT: Alanine Aminotransferase. Note that CD3/CD16 necrotic is the count of CD3 CD16 double positive cells in the necrotic tissue and stroma tissue counted together.
C-IBP approach when excluding patients with low drug exposure. Features F1, F2 and F3 (Additional files 5, 6, 7) were characterized by sets of biomarkers similar to those identified in the all-patient analysis, indicating that each major group characteristics are independent of drug exposure, and are intrinsic to the subjects in each group.

C-IBP deliberately includes all patients in order to learn a joint meaningful patient representation via latent features that manifest differently for different patients. The inclusion of patients that received low drug exposure allows discovering prognostic factors (in latent feature F1 and F2), as well as drug-specific effects (in latent feature F3) by sharing information (e.g., occurrence of correlation signatures) across patients with varying levels of drug exposure. Table 7 and Additional files 5, 6, 7 confirm the statistical significance of the discovered biomarkers by performing two-sample tests only on patients who received high drug exposure (but after having found a latent projection based on information from all patients).

### Table 4 Biomarkers significant for feature F3, ranked by effect size

| Continuous Variables | Effect Size | p-value   |
|----------------------|-------------|-----------|
| CD56dimCD16bright    | 1.27        | 2.18e-09  |
| NK                   | 1.24        | 2.13e-10  |
| CD56-CD16+           | 0.61        | 2.19e-06  |
| CD56dimCD16-         | 0.42        | 1.04e-05  |
| CD8 NK               | 0.37        | 7.13e-08  |
| DN                   | 0.27        | 3.73e-05  |
| CD16                 | 0.24        | 6.06e-10  |
| NKP46                | 0.22        | 1.14e-09  |
| CD8                  | 0.20        | 3.44e-09  |
| CD45                 | 0.14        | 5.09e-11  |
| CD3                  | 0.13        | 1.49e-08  |
| CD4                  | 0.12        | 5.06e-06  |

Feature F3 is represented by NK and T cell subpopulations. Hazard Ratio was 0.75 with 95% confidence interval [0.57; 1.00]. See Additional File 4 for details.

### Table 5 Biomarkers significant in subpopulation 4, ranked by effect size

| Continuous Variables | Effect Size | p-value   |
|----------------------|-------------|-----------|
| %Necrotic            | 2.73        | 1.86e-04  |
| CD3/CD16 necrotic    | 2.63        | 2.85e-04  |
| %Viable              | -0.86       | 1.86e-04  |
| CD3/CD16 viable      | -0.85       | 2.85e-04  |

Biomarkers significant for subpopulation 4 (subjects with longer PFS in placebo group), compared to subpopulations 1, 2 and 3 (subjects with short PFS in placebo group), ranked by effect size. Biomarkers as in Table 3.

### Table 6 Biomarkers significant for feature F3 in the treatment arm, ranked by effect size

| Continuous Variables | Effect Size | p-value   |
|----------------------|-------------|-----------|
| CD56dimCD16bright    | 1.36        | 1.76e-09  |
| NK                   | 1.33        | 9.51e-11  |
| CD56-CD16+           | 0.66        | 1.26e-06  |
| DP                   | 0.59        | 2.14e-04  |
| CD56dimCD16-         | 0.44        | 4.39e-06  |
| CD8 NK               | 0.39        | 9.50e-08  |
| DN                   | 0.30        | 3.58e-05  |
| NKP46                | 0.25        | 3.36e-10  |
| CD16                 | 0.25        | 3.29e-10  |
| CD8                  | 0.21        | 2.29e-04  |
| CD45                 | 0.15        | 3.75e-11  |
| CD3                  | 0.14        | 1.00e-08  |
| CD4                  | 0.14        | 1.48e-06  |

Feature F3 in the treatment group is represented by NK and T cell subpopulations. See Additional file 4 for details.

### Discussion

The identification of biomarkers in complex datasets affected by multiple confounding factors can be challenging. In drug development, clinical trials are powered to deal with situations of constant drug exposure, and traditional statistical methods have difficulties extracting signals from data confounded by factors like differential drug exposure. Therefore, sensitive analytical methods are needed to deconvolute real signals from biological and technical variability. We applied the Case-control Indian Buffet Process (C-IBP) to a phase II clinical study of Codrituzumab in HCC which had failed to meet the primary endpoint due to insufficient drug exposure [8]. Beyond GPC3 and CD16 expression, traditional statistical approaches did not render useful insights into potential biomarkers of response [8]. In contrast, the C-IBP analysis identified several biomarkers that stratified patient subgroups with statistical significance, and meaningful biology.

While variable drug exposure confounded previous statistical approaches such as regression models [8], C-IBP was able to unravel statistically significant biomarkers despite of the drug exposure confounder, which makes it particularly attractive and suitable for this kind of data. C-IBP learned a meaningful latent representation of patients by sharing information from all patients. The learned features were used to identify homogeneous subgroups of patients for whom classical statistical analyses were performed. Nonetheless, we remark that, although all statistical tests were independent, we cannot rule out all confounding effects across subgroups.
The C-IBP model identified two kinds of features: global features, which were active for patients regardless of treatment, and indicated prognostic markers, and drug-specific features, which were only allowed to be active for patients in the treatment arm, and were therefore linked to drug response. Global prognostic features included known prognostic markers in HCC, like alpha-fetoprotein [13] and GPC3 expression in the tumor [1]. In addition, global features included levels of inflammatory T and NK cells in tumor necrotic tissue and adjacent peri-tumoral stroma. In this regard, patients with higher levels of T and NK cells (identified by CD3/CD16 staining) in peri-tumoral stroma and lower levels in viable tumor cells had better prognosis, which is consistent with the role of these inflammatory cells in anti-tumor response [14, 15]. Drug-specific features included different NK cell subtypes, which confirms previous findings of the central role for NK cells in HCC [16]. Specifically, a reduction of blood CD56dimCD16+ right NK cells has been correlated with poor prognosis in HCC [17], and we observed that presence of this subset was the most predictive of positive drug response, both in the entire study and in the high exposure group (Tables 4 and 6). These findings are consistent with the mode of action of Codrituzumab, which requires engagement of the CD16/FcγRIIIa receptor in NK cells to recruit NK cells to the tumor with subsequent tumor lysis [5].

Conclusions
In summary, the C-IBP approach applied to a complex Phase II clinical study in HCC confounded by several factors was able to identify prognostic and predictive biomarkers of response to Codrituzumab. The C-IBP method is flexible, as it automatically infers the required number of latent features that best explain the observations. We were able to identify both prognostic and predictive variables, as well as quantify the direction of action, effect size and statistical significance for each biomarker. Our model handles data variability and missing information naturally. In order to deal with the small sample-size problem, C-IBP shares information among patients (by defining global features active for any patient, or drug-specific features, that are constrained by model design to eventually activate only for patients having taken the drug). By following such approach, there is a clear separation between drug effects and natural prognostic factors.

Additional files

Table 7 Subpopulations discovered by the C-IBP, only considering the high exposure group and placebo group

| Sub-population | Drug Identifier | F1 | F2 | F3 | Average num. of patients | Mean PFS (months) | Median PFS (months) |
|----------------|-----------------|----|----|----|--------------------------|------------------|--------------------|
| 1.             | 0               | 0  | 0  | 0  | 33.16                    | 3.07             | 1.65               |
| 2.             | 0               | 0  | 1  | 0  | 4.17                     | 2.30             | 2.21               |
| 3.             | 0               | 1  | 0  | 0  | 17.96                    | 2.70             | 1.81               |
| 4.             | 0               | 1  | 1  | 0  | 4.71                     | 7.02             | 7.15               |
| 5.             | 1               | 0  | 0  | 0  | 25.67                    | 4.15             | 3.93               |
| 6.             | 1               | 0  | 0  | 1  | 6.72                     | 4.64             | 4.23               |
| 7.             | 1               | 0  | 1  | 0  | 4.23                     | 2.96             | 2.29               |
| 8.             | 1               | 0  | 1  | 1  | 1.37                     | 3.69             | 3.67               |
| 9.             | 1               | 1  | 0  | 0  | 14.63                    | 3.62             | 2.66               |
| 10.            | 1               | 1  | 0  | 1  | 1.55                     | 5.94             | 5.93               |
| 11.            | 1               | 1  | 1  | 0  | 3.86                     | 6.23             | 5.37               |
| 12.            | 1               | 1  | 1  | 1  | 1.98                     | 10.63            | 10.62              |
| Total          | 60.00           |    | 44.69 | 20.31 | 11.61 | 120 | 3.78 | 2.76 |

The values are similar to those in Table 1, corresponding to the analysis performed in the entire cohort.

The C-IBP model identified two kinds of features: global features, which were active for patients regardless of treatment, and indicated prognostic markers, and drug-specific features, which were only allowed to be active for patients in the treatment arm, and were therefore linked to drug response. Global prognostic features included known prognostic markers in HCC, like alpha-fetoprotein [13] and GPC3 expression in the tumor [1]. In addition, global features included levels of inflammatory T and NK cells in tumor necrotic tissue and adjacent peri-tumoral stroma. In this regard, patients with higher levels of T and NK cells (identified by CD3/CD16 staining) in peri-tumoral stroma and lower levels in viable tumor cells had better prognosis, which is consistent with the role of these inflammatory cells in anti-tumor response [14, 15]. Drug-specific features included different NK cell subtypes, which confirms previous findings of the central role for NK cells in HCC [16]. Specifically, a reduction of blood CD56dimCD16+ right NK cells has been correlated with poor prognosis in HCC [17], and we observed that presence of this subset was the most predictive of positive drug response, both in the entire study and in the high exposure group (Tables 4 and 6). These findings are consistent with the mode of action of Codrituzumab, which requires engagement of the CD16/FcγRIIIa receptor in NK cells to recruit NK cells to the tumor with subsequent tumor lysis [5].

Additional file 1: Method description. (PDF 335 kb)
Additional file 2: List of biomarkers in this study and abbreviations. (XLSX 7 kb)
Additional file 3: Biomarker and clinical endpoint data. (CSV 51 kb)
Additional file 4: Relative effect size of biomarkers associated to each latent feature inferred by the C-IBP model. Significant biomarkers according to the Mann-Whitney test are marked with red circles. F1 identifies two types of patients with similar prognosis but different characteristics, F2 and F3 are associated with higher Progression Free Survival: F2 capture prognostic biomarkers while F3 capture predictive biomarkers. (PDF 85 kb)
Additional file 5: Biomarkers significant for feature F1 when only considering patients with high exposure and placebo. (XLSX 6 kb)
Additional file 6: Biomarkers significant for feature F2 when only considering patients with high exposure and placebo. (XLSX 6 kb)
Additional file 7: Biomarkers significant for feature F3 when only considering patients with high exposure and placebo. (XLSX 6 kb)

Abbreviations
ADCC: antibody-dependent cytotoxicity (ADCC); C-IBP: Case-control Indian Buffet Process; GPC3: Glypican-3; HCC: Hepatocellular carcinoma; IBP: Indian
Acknowledgements

We thank the patients, and their families, for supporting this investigation.

Funding

The study was funded by the sponsor (Roche), and designed by the sponsor and investigators. The trial was conducted in accordance with international conference on harmonisation Good Clinical Practice guidelines. Author MFP was supported by the European Union 7th Framework Programme through the Marie Curie Initial Training Network “Machine Learning for Personalized Medicine” MLPM2012, Grant No. 316861 (http://mlpm.eu), as well as the Harvard Data Science Initiative and Center for Computation and Society at Harvard. FPC received funding from MINECO/FEDER (“ADVENTURE”, id. TEC2015-69868-C2-1-R), and Comunidad de Madrid (project “CASI-CAM-CM”, id. S2013/ICE-2845). Neither of the funding bodies for MFP and FPC played a direct role in the design of the study, collection, analysis, interpretation of data, and writing of the manuscript.

Availability of data and materials

The dataset supporting the conclusions of this article is included as Additional file 3. For the analysis, we have used software from the general latent feature model toolbox (GLFM) project.

Project home page

e.g. https://github.com/ivaleraM/GLFM

Operating system(s)

Matlab (also available for python and R languages).

Other requirements

e.g. Matlab 2012b or higher, GNU GSL library, GMP library.

Authors’ contributions

Authors FPC and OP designed the study, authors MP, BR, LJ, TO, FM, and OP (project ‘FEDER (7Kite, a Gilead Company, Santa Monica, CA, USA). 8Translational Medicine, 1Harvard University, Cambridge, MA, USA. 9University Carlos III in Madrid, Leganés, Spain.

Received: 20 November 2018 Accepted: 14 March 2019

References

1. Shirakawa H, Konuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinosita H, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009;34:469–56.
2. Capurro MI, Xiang Y, Lobe C, Filmins J. Glypican-3 promotes the growth of hepatocellular carcinoma by stimulating canonical Wnt signaling. Cancer Res. 2005;65:6245–55.
3. Sun CK, Chua M-S, He J, So Samuel K. Suppression of Glypican 3 inhibits growth of hepatocellular carcinoma cells through up-regulation of TGFβ-2. Neoplasia. 2011;13:735–42.
4. Ishiguro T, Sugimoto M, Kinosita Y, Miyazaki Y, Nakano K, Tsunoda H, et al. Anti-glypican 3 antibody as a potential antitumor agent for human liver cancer. Cancer Res. 2008;68:9832–8.
5. Nakano K, Orita T, Nezu J, Yoshino T, Ohizumi I, Sugimoto M, et al. Anti-glypican 3 antibodies cause ADCC against human hepatocellular carcinoma cells. Biochem Biophys Res Commun. 2009;378:279–84.
6. Zhu AX, Gold PJ, El-Khoueiry AB, Abrams TA, Morikawa H, Ohishi N, et al. First-in-man phase I study of GC33, a novel recombinant humanized antibody against glypican-3, in patients with advanced hepatocellular carcinoma. Clin Cancer Res. 2013;19:920–8.
7. Ikeda M, Ohkawa S, Okusaka T, Mitsunaga S, Kobayashi S, Morizane C, et al. Japanese phase I study of GC33, a humanized antibody against glypican-3 for advanced hepatocellular carcinoma. Cancer Sci. 2014;105:455–62.
8. Abou-alfa GK, Puig O, Daniele B, Kudo M, Park J, Ross P, et al. Randomized phase II placebo-controlled study of codrituzumab in previously treated patients with advanced hepatocellular carcinoma. J Hepatol [Internet]. European Association for the Study of the. Liver. 2016;65:289–95. Available from: https://doi.org/10.1002/hep.20400.
9. Valera I, Pradier MP, Lomeli M, Ghahramani Z. General Latent Feature Models for Heterogeneous Datasets. arXiv preprint arXiv:1706.03779, 2017. Available from: https://arxiv.org/abs/1706.03779.
10. Rossmann ED, Lenkei R, Lundin J, Millstedt H, Ostberg A. Performance of calibration standards for antigen quantitation with flow cytometry in chronic lymphocytic leukemia. Cytometry B Clin Cytom. 2007;72:450–7.
11. Haruyama Y, Yorita K, Kamiyachi T, Kitajima S, Amano J, Ohtomo T, et al. High preoperative levels of serum glypican-3 containing N-terminal subunit are associated with poor prognosis in patients with hepatocellular carcinoma after partial hepatectomy. Int J Cancer. 2015;137:1643–51.
12. Benjamini Y, Hochberg Y. Controlling the false discovery rate: a practical and powerful approach to multiple testing. J R Stat Soc. 1995;57:289–300.
13. Nomura F, Ohashi K, Tanabe Y. Clinical features and prognosis of hepatocellular carcinoma with reference to serum alpha-fetoprotein levels. Analysis of 606 patients. Cancer. 1983;64:1700–7.
14. Wu Y, Kuang DM, Pan WD, Le WY, Lao XM, Wang D, et al. Monocyte/macrophage-elicited natural killer cell dysfunction in hepatocellular carcinoma is mediated by CD48/2B4 interactions. Hepatology. 2013;57:1107–16.
15. Galon J, Pagès F, Marincola FM, Thrun J, Trinchieri G, Fox BA, et al. The immune score as a new possible approach for the classification of cancer. J Transl Med. 2012;10:1–4.
16. Sun C, Sun H, Xiao W, Zhang C, Tian Z. Natural killer cell dysfunction in hepatocellular carcinoma and NK cell-based immunotherapy. Acta Pharmacol Sin. 2015;36:1191–9.
17. Cai L, Zhang Z, Zhou L, Wang H, Fu J, Zhang S, et al. Functional impairment in circulating and intrahepatic NK cells and relative mechanism in hepatocellular carcinoma patients. Clin Immunol. 2008;129:428–37.